Back

Advanced biologic therapies are associated with fewer adverse cardiovascular events in patients with inflammatory bowel diseases

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Autoimmune and chronic inflammatory disorders and heart disease (2) Autoimmune/Chronic Inflammatory Disorders and Heart Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Tarek Harb

The Johns Hopkins University School of Medicine, Baltimore (United States of America)

8 More presentations in this session

Presentation thumbnail
Chronic inflammation is associated with impaired cardiac structure and function in patients with inflammatory arthritis: the ARTCADIA Study
Doctor M. Sengelov (Hellerup, DK)
Abstract Slides Video
Presentation thumbnail
Vascular thrombosis and relapse-associated factors in Behcet's syndrome: a comprehensive analysis of 136 patients
Doctor S. Chadli (Rabat, MA)
Abstract Slides Video
Presentation thumbnail
The potential effects of methotrexate on cardiovascular outcomes in rheumatoid arthritis patients: a multi-institutional analysis
Doctor M. Cervantes (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Association of inflammation with left ventricular mass index in patients with rheumatoid arthritis
Doctor A. Linde (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Cardiac structure and function in patients with chronic obstructive pulmonary disease
Doctor D. Vesterlev (Copenhagen, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Autoimmune and chronic inflammatory disorders and heart disease (2)

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Histologic remission and major adverse cardiovascular events in patients with inflammatory bowel disease: a nationwide cohort study
thumbnail
Congress Presentation
Dysbiotic microbiome induce cardiac impairment by attenuating brain-derived neurotrophic factor in inflammatory bowel diseases
thumbnail
Congress Presentation
Effect of interleukin 1b inhibition with canakinumab on inflammation and viral persistence in people with human immunodeficiency virus

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources